Board of Directors

  • Kirk Malloy, Ph.D. Chairman of the Board Chief Executive Officer, Verogen, Inc. Founder and Principal, BioAdvisors, LLC
  • Robert Baltera, Jr. Chief Executive Officer, Cirius Therapeutics, Inc. Entrepreneur-in-Residence, Frazier Healthcare Partners
  • Taylor J. Crouch President and Chief Executive Officer
  • James T. Glover Former Chief Financial Officer, Anadys Pharmaceuticals, Inc. and Beckman Coulter, Inc.
  • Tamar D. Howson Former Executive Vice President of Corporate and Business Development, Lexicon Pharmaceuticals
  • Mark Kessel Co-Founder and Partner, Symphony Capital, LLC Of Counsel, Shearman & Sterling LLP
  • Richard Maroun Executive Partner, Frazier Healthcare Partners

Management Team

  • Taylor J. Crouch President and Chief Executive Officer
  • Craig Kussman Chief Financial Officer
  • Sharon Collins Presnell, Ph.D. Chief Scientific Officer President, Samsara Sciences Inc.
  • Paul Gallant General Manager
  • Jennifer Kinsbruner Bush, J.D. General Counsel, Corporate Secretary and Compliance Officer

General Information

  • Corporate Headquarters
    6275 Nancy Ridge Drive San Diego, CA 92121
    (858) 224-1000
  • Transfer Agent and Registrar Continental Stock Transfer and Trust Company
    1 State Street Plaza, 30th Floor New York, NY 10004
    (800) 509-5586
  • Independent Registered Public Accounting Firm Mayer Hoffman McCann P.C.
    10616 Scripps Summit Court San Diego, CA 92131
    (858) 795-2000

Investor Information

  • Stock Exchange NASDAQ Global Market Common Stock (ONVO)
  • Information Requests Copies of the Company’s Annual Report on Form 10-K and other investor information are available to stockholders upon written request to:
    Organovo Holdings, Inc. Attention: Investor Relations 6275 Nancy Ridge Drive San Diego, CA 92121
  • Investor Inquiries Steve E. Kunszabo Vice President, Investor Relations and Corporate Communications (858) 224-1092
  • 2018 Annual Meeting

    The Annual Meeting of Stockholders will be held on July 26, 2018 at 9:00 a.m. local time at Green Acre Campus Pointe, 10300 Campus Point Drive, San Diego, CA, 92121

Safe Harbor Statement

Any statements contained in this Annual Report that do not describe historical facts are forward-looking statements as defined under the Federal securities laws. The Company has based these forward-looking statements on its current expectations and the information currently available to it, but any forward-looking statements are subject to a number of risks and uncertainties. The factors that could cause the Company’s actual future results to differ materially from its current expectations, or from the results implied by any forward-looking statements, include, but are not limited to, the final results of the Company's preclinical studies may be different from the Company's studies or interim preclinical data results and may not support further clinical development of its therapeutic tissues; the Company may not successfully complete the required preclinical and clinical trials required to obtain regulatory approval for its therapeutic tissues on a timely basis or at all; risks and uncertainties relating to the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the Company’s ability to successfully complete studies and provide the technical information required to support market acceptance of its products, services and technology, on a timely basis or at all; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies, including its use of third party distributors; the Company’s ability to recognize deferred revenue; the Company’s ability to raise sufficient funds to finance its long-term business plan; and the Company’s ability to meet its fiscal year 2019 goals. These and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2018. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.